Annual Report 2023

Financial ReportConsolidated financial statementsConsolidated statement of changes in equity

Financial Report

Consolidated statement of changes in equity

1 January - 31 December

Attributable to shareholders of PolyPeptide Group AG:


kEUR	Share capital	Share premium	Translation reserve	Treasury shares	Other capital reserves	Retained earnings	Total

Balance as at 1 January 2023	302	203,129	14,119	-13,609	3,590	214,146	421,677

Result for the year						-51,440	-51,440
Remeasurement gain / (loss) on defined benefit plans, net of tax						2,433	2,433
Currency exchange differences			7,713				7,713
Total comprehensive income	–	–	7,713	–	–	-49,007	-41,294

Purchase of own shares							–
Dividends paid							–
Share-based payment					842		842
Transfer of own shares				3,215	-3,215		–
Total transactions with owners	–	–	–	3,215	-2,373	–	842
Balance as at 31 December 2023	302	203,129	21,832	-10,394	1,217	165,139	381,225

1 January - 31 December

Attributable to shareholders of PolyPeptide Group AG:


kEUR	Share capital	Share premium	Translation reserve	Treasury shares	Other capital reserves	Retained earnings	Total

Balance as at 1 January 2022	302	212,800	9,285	-1,187	3,946	196,027	421,173

Result for the year						7,767	7,767
Remeasurement gain / (loss) on defined benefit plans, net of tax						10,352	10,352
Currency exchange differences			4,834				4,834
Total comprehensive income	–	–	4,834	–	–	18,119	22,953

Purchase of own shares				-13,933			-13,933
Dividends paid		-9,671					-9,671
Share-based payment					1,155		1,155
Transfer of own shares				1,511	-1,511		–
Total transactions with owners	–	-9,671	–	-12,422	-356	–	-22,449
Balance as at 31 December 2022	302	203,129	14,119	-13,609	3,590	214,146	421,677